Here are three things to know.
1. The upfront payments were not disclosed, however, Kineta is eligible to receive up to $359 million on top of royalty payments.
2. Genentech has the ability to license technologies developed from the collaborations.
3. Early tests of the drug are displaying disease-modifying effects, such as reduced information and nerve protection.
4. Roche purchased Genentech for $46.8 billion in 2009.
5. Kineta was founded in 2008 to develop drugs for chronic pain, autoimmune and infectious diseases.
More articles on devices and implants:
NovoStitch Pro Meniscal Repair System receives FDA 510(k) clearance: 4 insights
Global spinal fusion devices market to grow at 4.6% CAGR through 2025: 4 observations
Dr. Richard Moore performs 1st surgery with Zimmer Biomet’s Persona Trabecular Metal Tibia: 5 notes
